Minimizing side effects from chemoradiation could help brain cancer patients live longer

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

The researchers found that the occurrence of early , such as fatigue and loss of short-term memory, that manifest during or soon after treatment is significantly associated with both late side effects (after 90 days) and overall survival in patients who suffer from malignant , such as glioblastoma.

High-grade glioma patients who did not experience neurological side effects during chemoradiation for the brain cancer were found to have lived 4 months longer compared to those who did experience such effects.

The findings suggest the importance of normal tissue damage in determining long-term survival and how minimizing side effects could end in more positive outcomes.

The team reports their findings from a retrospective analysis of high-grade glioma patients from the Radiation Therapy Oncology Group (RTOG) database.

"As survival in glioblastoma multiforme increases, the prevention of treatment related side-effects becomes more important," said Yaacov Richard Lawrence, MRCP, an Assistant Professor in the Department of at Thomas Jefferson University and director of the Center for Translational Research in Radiation Oncology at Sheba Medical Center in Israel.

"It is generally considered that the only way to improve survival in malignant brain tumors is to more effectively attack the tumor," Dr. Lawrence said. "Fascinatingly, our research suggests that damage to surrounding normal tissue may also play a role in determining a patient's long term outcome."

There are approximately 17,000 primary brain tumors diagnosed in the United States each year, 60 percent of which are gliomas. The most common and malignant glioma is glioblastoma, the type of Senator Ted Kennedy was diagnosed with and died from.

Standard treatment for the cancer typically includes surgery, radiation and chemotherapy after the tumor is identified. It is often impossible to determine whether these treatments, the combination of these treatments or the tumor itself cause neurological symptoms, which include fatigue, headache, nausea, motor/sensory disturbance, short-term memory loss and/or seizures.

For the study, researchers analyzed data amongst 2,761 patients from 14 RTOG radiation therapy glioma studies that accrued patients from 1983 to 2003. Patients considered were more likely to have side effects if they were older, frailer, had more symptoms, and were receiving radiation twice daily.

"Our results support the personalized approach to brain tumor management currently being developed within the Jefferson Multidisciplinary Brain Clinic, and emphasize the importance of minimizing side effects," Dr. Lawrence said.

Related Stories

Acute toxicity predicts overall survival in high-grade gliomas

date Jun 07, 2010

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers ...

Brain tumor vaccine has promising results

date Nov 22, 2006

U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.